Arrow Dx has been selected as one of the 15 companies that will compete in the 2020 $200K M2D2 Challenge in Lowell, MA in Fall 2020. The 2020 $200K M2D2 Challenge received 250+ applications this year.
Blood Diagnostics with Nanoscale Precision
Arrow Dx is developing highly sensitive detection chips that can be incorporated into portable sensors. The versatility of our technology allows for use in a variety of applications ranging from early disease detection to environmental pollutant detection to quality control in the wine industry.
The ability to detect small molecules, viruses, bacteria and proteins in blood is an important tool in the fight against disease. Our proprietary technology allows for an enhanced detection method necessary for the early diagnosing of many diseases such as COVID-19, E.coli, and non-alcoholic fatty liver disease (NAFLD) such that an effective treatment can be found thus making it easier for both the patient and physician.
Protein conformational changes are often a strong indicator of a medicine’s effectiveness on an individual patient. Arrow Dx is currently developing methods to apply its technology to further the development of biopharmaceuticals and the pursuit of enhanced personalized medicine.
Our mission is to harness the powerful applications of machine learning and predictive analytics to enhance diagnostic medicine. Using proprietary algorithms we are working to develop single protein and metabolite sensitivity.